Free Trial
NASDAQ:PFSA

Profusa Q2 2026 Earnings Results & Report

Profusa logo
$1.42 -0.07 (-4.70%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.06 (+3.87%)
As of 10/9/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Profusa reported Q2 2026 earnings on August 19, 2026. The company reported EPS of -$151.80.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Profusa EPS Results

Actual EPS
-$151.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Profusa Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Profusa Q2 2026 Earnings FAQ

Profusa (NASDAQ:PFSA) reported earnings of -$151.80 per share for Q2 2026. The report was announced on Wednesday, August 19, 2026.

Profusa Earnings Headlines

Here’s What Investors Are Watching, Including $20 Price Target Bombshell
Elon just declared war on your phone
SpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.tc pixel
Profusa Advances Lumee Oxygen Platform Toward CE Mark
See More Profusa Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Profusa? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profusa and other key companies, straight to your email.

About Profusa

Profusa (NASDAQ:PFSA) is a biotechnology company developing implantable biosensor technology designed to continuously monitor body chemistry. Its sensors are engineered to integrate with tissue and detect selected biological signals, with the goal of providing real-time health data through an external reader or connected digital device.

The company’s technology platform has been studied for applications including monitoring oxygen and other biomarkers that may assist with disease management, clinical research, and personalized healthcare. Profusa has also developed the Lumee oxygen-sensing system and has explored additional uses for its biosensors in areas such as chronic-condition monitoring and remote patient care.

Profusa’s work has included collaborations and research programs involving government and healthcare organizations. The company’s technology remains focused on developing less invasive, continuous monitoring solutions that could complement conventional laboratory testing and periodic measurements.

View Profusa Profile